Aprepitant
As of the edition of 20 October 2026, Aprepitant is a small molecule: marketed, first approved in 2003 (US); acts on TACR1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2009
- Kind
- Small molecule
- Brand name
- Emend
- First approved
- 26 March 2003 (US)
- Approvals on record
- 14 in 5 regions
- Holder of the most recent approval
- Azurity Pharmaceuticals; 4 holders in all
- Registered trials
- 135, 17 stopped early
- Disease areas
- Cancer; Blood and lymph; Mental health; Skin and connective tissue; Immune system; Hormones
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Aprepitant.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TACR1 | Substance-P receptor | P25103 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 19 | 11 | 1 | 6 |
| Phase 1 | 17 | 12 | 2 | 1 |
| Phase 2 | 32 | 23 | 2 | 4 |
| Phase 3 | 42 | 33 | 0 | 2 |
| Phase 4 | 25 | 13 | 3 | 4 |
| All trials | 135 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Originator and Lead sponsor of trials | 2001 to now |
| Ono Pharmaceutical | Applicant and Lead sponsor of trials | 2005 to now |
| Heron Therapeutics | Later holder and Lead sponsor of trials | 2017 to now |
| Azurity Pharmaceuticals | Later holder | 2026 to now |